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Hazardous alcohol consumption and HIV infection increase the risk of neurocognitive
impairment (NCI). We examined the association between alcohol consumption and specific
neurocognitive domain function in people with HIV (PWH) taking modern antiretroviral
therapy.
Methods
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is a
prospective, longitudinal, multicentre and multilingual (French, German and Italian) study of
patients aged�45 years old enrolled in the Swiss HIV Cohort Study (SHCS). Baseline data
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from 981 study participants were examined. Five neurocognitive domains were evaluated:
motor skills, speed of information processing, attention/working memory, executive function
and verbal episodic memory. NCI was examined as binary (presence/absence) and continu-
ous (mean z-score) outcomes against Alcohol Use Disorders Identification Test for Con-
sumption (AUDIT-C) scores using logistic and linear regression models, respectively.
Results
Most participants (96.2%) had undetectable viral loads and 64% were aged >50 years old.
Hazardous alcohol consumption was observed in 49.4% of participants and binge drinking
in 4.2%. While alcohol consumption frequency and quantity were not associated with NCI,
the practice of binge drinking was significantly associated with impaired motor skills and
overall neurocognitive function in both binary (odds ratio, OR�2.0, P <0.05) and continuous
(mean z-score difference -0.2 to -0.4, P�0.01) outcomes. A significant U-shaped distribu-
tion of AUDIT-C score was also observed for motor skills and overall neurocognitive
function.
Conclusions
In this cohort of PWH with well-controlled HIV infection, NCI was associated with the prac-
tice of binge drinking rather than alcohol consumption frequency or quantity. Longitudinal
analysis of alcohol consumption and NCI in this population is currently underway.
Introduction
HIV-associated neurocognitive impairment (NCI) represents a clinical challenge which will
grow as people with HIV (PWH) continue to age. In the era of modern and highly efficacious
antiretroviral therapy (ART), potentially modifiable factors affecting HIV course such as alco-
hol consumption merit review.
The combination of hazardous alcohol consumption and HIV appears to have an associa-
tion with NCI beyond that of alcoholism or HIV as single diagnoses [1]. Among PWH, alcohol
consumption is generally higher than that observed among HIV-negative peers [2,3]. Hazard-
ous alcohol consumption has been observed to be associated with impaired health-related
quality of life, impaired ART adherence and ART interruption, all of which potentially affect
neurocognitive function [4–7]. Furthermore, in PWH of increasing age, previous hazardous
consumption appears to maintain an association with NCI [8–11].
NCI severity in PWH is often characterised according to the Frascati criteria and this
enables comparison between different patient cohorts [12,13]. An important disadvantage of
the Frascati criteria, where NCI requires deficits in two or more neurocognitive domains, is
that deficits in a single domain will be missed. Another disadvantage of the Frascati criteria is
that a binary approach of NCI versus no NCI will miss more subtle differences in z-score val-
ues. Among HIV-negative individuals, alcohol has been reported to cause global NCI but also
both focal deficits affecting specific neurocognitive domains [14–16]. When examining associ-
ations between hazardous alcohol consumption (for which there is no uniform definition) and
NCI, neurocognitive assessment therefore needs to be tailored carefully. If the effects of alcohol
consumption on NCI vary in PWH over time, as has been described among HIV-negative
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individuals [14], this will be detected only if a detailed neuropsychological assessment is per-
formed at baseline.
To date, there are relatively few studies on the association between alcohol consumption
and NCI in the modern ART era (post-2013) beyond prevalence studies [3]. It is unclear
whether the effects of alcohol consumption on neurocognitive function are still compounded
by HIV when infection is well-controlled. We examined the association between NCI and alco-
hol consumption among persons enrolled in a large Swiss cohort set up specifically to examine
NCI, the Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study.
Materials and methods
Setting and participants
The NAMACO study is a prospective, longitudinal, multicentre and multilingual (French,
German and Italian) study of patients nested within the Swiss HIV Cohort Study (SHCS) [17].
Inclusion criteria at enrolment into the NAMACO study were age�45 years old, HIV-positive
status, enrolment in the SHCS and engagement in care at one of seven SHCS hospital centres
(five university-affiliated and two cantonal) (Basel, Bern, Geneva, Lausanne, Zurich, Lugano
and St-Gallen). Insufficient oral fluency in the local language to enable neuropsychological
testing was the only exclusion criterion [18]. NAMACO participants undergo standardized
neurocognitive assessment at inclusion (baseline: between 1st May 2013 and 30th November
2016) and then at two (2016–2018) and four years (2018–2020) from inclusion. The current
study examined the baseline data set of 981 NAMACO study participants.
Ethics approval and consent to participate. The ethics committees of each cantonal hos-
pital centre (Ethikkommission Nordwest- und Zentralschweiz EKNZ in Basel, Kantonale
Ethikkommission Bern in Bern, Commission Cantonale d’Ethique de la Recherche sur l’être
humain in Geneva, Commission cantonale d’éthique de la recherche sur l’être humain in Lau-
sanne, Ethikkommission Tessin in Lugano, Ethikkommission Ostschweiz EKOS in St-Gallen
and Ethikkommission Zürich in Zurich) approved the NAMACO study protocol. All partici-
pants signed informed consent prior to being included.
Study design
Neurocognitive assessment. Neurocognitive assessment in the NAMACO study has been
described in detail elsewhere [18,19]. Briefly, assessments were conducted by trained neuro-
psychologists using a neuropsychological test battery which covered five neurocognitive
domains: motor skills, speed of information processing, attention/working memory, executive
function and verbal episodic memory. The test battery was based on that used in the Interna-
tional Network for Strategic Initiatives in Global HIV Trials (INSIGHT) and the Strategic
Timing of AntiRetroviral Treatment START study group [13]. Each neuropsychological test
employed was specific to one of the five neurocognitive domains to avoid unfair weighting of
tests due to multiple use (S1 File). The raw score for each neuropsychological test was con-
verted to a demographically adjusted standard score (z-score). NCI was defined according to
Frascati criteria as having impairment in at least two out of the five neurocognitive domains
[12]. Degrees of NCI were defined as follows: asymptomatic impairment was defined as a
decrease of�1.0 standard deviation (SD) below normative data in�2 neurocognitive domains
without functional impairment; mild neurocognitive disorder was defined as a decrease of
�1.0 SD in�2 neurocognitive domains with functional impairment and HIV-associated
dementia was defined as a decrease�2.0 SD in�2 neurocognitive domains with functional
impairment [12]. Functional impairment was assessed using Lawton’s Instrumental Activities
of Daily Living (IADL) [20,21] and three supplementary questions on work quality and
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relatives’ observations regarding cognitive decline based on the Patients’ Assessment of Own
Functioning Inventory questionnaire (S2 File) [18,19].
Alcohol consumption. Alcohol consumption was quantified using the three-item Alcohol
Use Disorders Identification Test for Consumption (AUDIT-C) [22,23]. AUDIT-C examines:
1) the frequency of alcohol consumed, 2) the quantity (where one alcoholic drink approximates
to 10g of alcohol) and 3) the practice of binge drinking (>six alcoholic drinks in a single sitting).
Each question scores between 0 and 4 points and scores are combined to give a total score of
between zero and 12. Hazardous drinking in this study was defined as AUDIT-C scores�4 in
men and�3 in women [3,24]. AUDIT-C scores were examined by category (frequency, quan-
tity and binge) and by total score. Data on alcohol consumption among participants in the
SHCS are collected at twice-yearly standardized infectious diseases clinic visits. For this study,
AUDIT-C scores were obtained from the SHCS database using the extraction from just prior to
the neuropsychological assessment. The median interval between AUDIT-C score collection
and neuropsychological assessment was 36.5 days (IQR 13.5;73). For participants with an
AUDIT-C score of zero, we examined SHCS data and local medical records to determine
whether abstinence was related to prior hazardous alcohol consumption or to life-long absti-
nence. Patient demographic factors (age, sex, ethnicity, education level), HIV history and data
on drug use, injecting and non-injecting, were also obtained from the SHCS database.
Statistical analysis. Descriptive analyses are presented as mean (SD) for symmetric continu-
ous variables, median (interquartile range, IQR) for asymmetric continuous variables and as percent-
ages for categorical variables. We defined binary (presence/absence of NCI according to Frascati
criteria as described above) and continuous (mean z-score) outcomes for each of the five neurocog-
nitive domains and for overall neurocognitive function. The continuous outcome for each neurocog-
nitive domain was defined as the mean of the z-scores of the neuropsychological tests used. Overall
neurocognitive function was the mean of the z-score means of the five neurocognitive domains [18].
The association between the variables defining alcohol consumption (frequency, quantity,
binge and total AUDIT-C score) and NCI was examined using logistic regression models for
the binary NCI outcome and linear regression models for the continuous outcome, adjusted
for sociodemographic variables (age, sex, origin, education level and drug use). Given that this
is a multi-centre study, we performed a sensitivity analysis adjusting for study centre and
observed that such adjustment had minimal effects on the associations we report as significant.
AUDIT-C score was analysed in four models: frequency, quantity, binge drinking and total
score. The first three models used binary outcomes where frequency�2–4 times a week was
coded as 1 and lower frequencies were coded as zero, quantity�3–4 drinks was coded as 1
while lower quantities were coded as zero, and binge drinking > once a week was coded as
one and� once a week was coded as zero. For the total AUDIT-C score model, the combined
scores for frequency, quantity and binge (giving a score of zero to twelve) were taken as contin-
uous covariables. The association between total AUDIT-C score and NCI (binary and continu-
ous outcomes) was examined introducing into the model the total AUDIT-C score (total
score) and the total AUDIT-C score squared (total score2), the latter to test for a quadratic
association between AUDIT-C score and NCI.
Statistical analyses were conducted using R Development Core Team version 3.2 2015 (R
Foundation for Statistical Computing, Vienna, Austria; www.R-project.org).
Results
NAMACO participants
The demographic details of the 981 NAMACO study participants have been described else-
where [25]. Briefly, 782 (79.7%) were male, 899 (91.7%) Caucasian and 627 participants
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(63.9%) were aged>50 years old (mean age 54.5±7.5 years). At baseline, most participants
(942, 96.2%) had viral loads <50 copies/ml; median CD4+ T cell count was 634 cells/mm3
(IQR 468;814) and median nadir CD4+ count was 180 cells/mm3 (IQR 74;270) (Table 1).
Alcohol consumption
Complete AUDIT-C score data were available for 970 participants (98.9%). Median AUDIT-C
score was 2 (IQR 1;4). Hazardous drinking was observed in 479/970 participants (49.4%): 422/
774 men (54.5%) with AUDIT-C scores�4 and 57/196 women (29.1%) with AUDIT-scores
�3. Fig 1 shows the distribution of AUDIT-C scores and Fig 2 shows the distribution of the
three AUDIT-C score categories of frequency, quantity and binge.
Of 186 participants (19.2%) with an AUDIT-C score of zero, 86 (46.2%) had a history of
life-long abstinence prior to NAMACO study inclusion, 62 participants (33%) had a history of
alcohol consumption with binge scores�1 and 38 (20.4%) had binge scores >1 and/or medi-
cal record documentation of prior hazardous consumption.
Table 1. Characteristics of patients participating in the NAMACO study.
Values
Age, mean (SD) 54.5 (7.5)
Male sex, n (%) 782 (79.7)
Caucasian, n (%) 899 (91.7)
Years of education, mean (SD) 13 (2.8)
Likely mode of HIV acquisition
Men who have sex with men, n (%) 506 (51.6)
Heterosexual, n (%) 325 (33.1)
IDU, n (%) 118 (12.0)
Other/unknown, n (%) 32 (3.3)
Alcohol, tobacco and drug consumption:
�3 drinks during a typical day, n (%) 20 (2.5)
�1 binge per month, n (%) 63 (7.9)
Cigarette smoking, n (%) 319 (36.7)
History of previous IDU, n (%) 137 (14.0)
Current non-IDU use:
Current cannabis use, n (%) 103 (10.5)
Current cocaine use, n (%) 16 (1.6)
HIV parameters:
HIV VL < 50 copies/mm3, n (%) 942 (96.2)
Current CD4 count, median [IQR] 634 [468–814]
Nadir CD4 count, median [IQR] 180 [74–270]
On ART, n (%) 959 (97.8)
ART duration, years, median [IQR] 12.7 [6.5–18]
Neurocognitive function (Frascati criteria):
Normal neurocognitive function 591 (60.2%)
Asymptomatic neurocognitive impairment 249 (25.4%)
Mild neurocognitive disorder 8 (0.8%)
HIV-associated dementia 6 (0.6%)
Other 127 (13.0%)
Abbreviations: SD, standard deviation; IDU, injecting drug use; VL, viral load; IQR, interquartile ratio; ART,
antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0246579.t001
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Binary outcome (presence/absence of NCI). Alcohol consumption was examined first
taking all 970 participants with complete AUDIT-C score data and then excluding the 38 partic-
ipants with AUDIT-C scores of zero at NAMACO study inclusion who had previous histories
of hazardous alcohol consumption. Alcohol consumption frequency and quantity, when exam-
ined as single variables, were not significantly associated with NCI (Table 2). Taking all partici-
pants, binge drinking was significantly associated with impaired motor skills (OR 2.4, P = 0.01)
and speed of information processing (OR 2.2, P = 0.02) (Table 2). Excluding participants with
AUDIT-C scores of zero but with previous hazardous alcohol consumption extended the binge
drinking association to include overall neurocognitive function (OR 2.0, P = 0.04).
We observed a significant quadratic association between AUDIT-C score and motor skills
and overall neurocognitive function. As the AUDIT-C score increased from zero to 12, we
observed an initial increase (for low scores) in the risk of NCI followed by a significant increase
for higher scores (linear AUDIT-C score OR 0.88, P = 0.115; quadratic AUDIT-C score OR
1.02, P = 0.03 for motor skills; linear AUDIT-C score OR 0.82, P = 0.02; quadratic AUDIT-C
score OR 1.02, P = 0.025 for overall neurocognitive function) (Fig 3).
Continuous outcome (mean z-score). Again, analyses were performed taking all partici-
pants and then after excluding participants with AUDIT-C scores of zero but with previous
hazardous alcohol consumption. As with the binary outcome, alcohol consumption frequency
and quantity were not significantly associated with NCI (Table 2). Binge drinking was signifi-
cantly associated with impaired motor skills (mean z-score difference -0.39, P = 0.001), execu-
tive function (mean z-score difference -0.21, P = 0.02) and overall neurocognitive function
(mean z-score difference -0.20, P = 0.01) (Table 2).
Fig 1. Distribution of total AUDIT-C scores among 981 study participants. Total AUDIT-C score is the sum of the three
scores for frequency, quantity and binge drinking. Abbreviations: IDU, injecting drug use.
https://doi.org/10.1371/journal.pone.0246579.g001
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We observed a significant quadratic association between AUDIT-C score and motor skills
and executive function z-scores. As the AUDIT-C score increased from zero, we observed an
initial reduction (for low scores) of the mean z-score followed by a significant reduction for
higher scores (linear AUDIT-C score z-score difference 0.039, P = 0.184; quadratic AUDIT-C
score z-score difference -0.008, P = 0.029 for motor skills; linear AUDIT-C score z-score
Fig 2. Distribution of alcohol consumption frequency and quantity and binge drinking among 981 study participants. The
numbers above each bar in the three bar plots represent the number of participants with each score. 1The numbers 0 to 4 are the scores
assigned to each possible response in the AUDIT-C score questionnaire. The response options are written below each bar for the three
categories of frequency, quantity and binge. Taking the category ‘frequency’ as an example, ‘never’ scores 0, while ‘>4 times a week’
scores 4.
https://doi.org/10.1371/journal.pone.0246579.g002
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difference 0.051, P = 0.016; quadratic AUDIT-C score z-score difference -0.006, P = 0.02 for
executive function) (Fig 3).
Repeating the continuous outcome analyses excluding participants with AUDIT-C scores
of zero but previous hazardous consumption did not change NCI associations. For both binary
Table 2. Associations between alcohol consumption and neurocognitive function.









OR P-value OR P-value OR P-value OR P-value OR P-value OR P-value
Frequency 0.93 0.60 1.03 0.86 0.70 0.02 0.86 0.38 1.06 0.77 0.89 0.44
Quantity 2.56 0.32 1.68 0.55 0.00 0.97 0.46 0.51 0.73 0.78 1.16 0.87
Binge drinking 2.42 0.01 2.15 0.02 0.91 0.80 1.23 0.59 0.79 0.61 1.90 0.06�
Total score 0.88 0.12 0.94 0.48 0.88 0.14 0.87 0.14 1.04 0.69 0.82 0.02
(Total score)2 1.02 0.04 1.01 0.30 1.01 0.51 1.02 0.20 0.99 0.44 1.02 0.03









Effect P-value Effect P-value Effect P-value Effect P-value Effect P-value Effect P-value
Frequency 0.00 0.96 0.01 0.92 0.16 0.001 0.04 0.33 -0.02 0.69 0.03 0.33
Quantity -0.39 0.22 -0.02 0.95 0.50 0.10 0.13 0.57 0.03 0.92 0.04 0.83
Binge drinking -0.39 0.001 -0.24 0.08 -0.03 0.79 -0.21 0.02 -0.12 0.30 -0.20 0.01
Total score 0.04 0.18 0.04 0.29 0.05 0.09 0.05 0.02 -0.01 0.72 0.03 0.07
(Total score)2 -0.01 0.03 0.00 0.32 0.00 0.53 0.01 0.02 0.00 0.58 -0.00 0.90
Neurocognitive function, examined by neurocognitive domain and overall, was examined in four models of alcohol consumption derived from the AUDIT-C score:
frequency, quantity, binge drinking and total AUDIT-C score. All models were adjusted for sociodemographic factors and drug use. Effect in the continuous model
refers to mean z-score difference. P-values in bold text indicate significant associations with impaired neurocognitive function.
Abbreviations: OR, odds ratio.
�In the analysis excluding participants with AUDIT-C scores of zero who had previous hazardous alcohol consumption, the odds ratio was 2.0, P = 0.04.
https://doi.org/10.1371/journal.pone.0246579.t002
Fig 3. Probability of NCI (binary outcome) and mean z-score (continuous outcome), for each neurocognitive domain and overall
NCI, as a function of the AUDIT-C score. NCI is adjusted for sociodemographic variables and drug use, and evaluated at reference values
of binary covariates (male, Caucasian and no drug use) and at mean values of age and education level.
https://doi.org/10.1371/journal.pone.0246579.g003
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and continuous outcomes, associations with drug use and NCI were minor and inconsistent
across models.
Discussion
In this large Swiss population of PWH aged�45 years old with well-controlled HIV infection,
we observed that hazardous alcohol consumption was more frequently reported among men
than women. Whether NCI was considered as a binary (presence/absence) or continuous
(mean z-score) outcome, we observed an association between binge drinking and impaired
motor skills and overall neurocognitive function. No such associations with NCI were
observed with alcohol consumption frequency or quantity. Finally, we observed a U-shaped
distribution in which participants with AUDIT-C scores of zero had worse neurocognitive
function compared to those with low and moderate alcohol consumption.
This is the first study in Switzerland to examine the association between alcohol consump-
tion and neurocognitive function in any patient group. Among our participants, hazardous
alcohol consumption, according to the definition used in our study, was observed in 49.4%.
Comparing our findings to another study performed in the modern ART era among 8567
PWH from seven US sites, we observed lower binge drinking levels [3]. Using the binge defini-
tion in this US study (less than monthly and more frequently), we observed binge drinking
among 18% of participants compared to their figure of 34% (the US study did not provide a
figure for binge drinking using our definition of at least weekly). However, the patients in the
US study were younger than participants in our study, with a mean age of 46 years and 41%
aged� 50 years. The fact that we did not identify an association between drug use and NCI
might be related to the relatively small proportion of participants who reported drug use, or
indeed to underreporting, but is also in keeping with previous studies [25,26].
The possible protective effect of low to moderate alcohol consumption has been described
among HIV-negative persons. In a review of 143 papers examining cognitive risk, light to moder-
ate alcohol consumption appeared to reduce the risk of cognitive decline in older subjects [16].
The small increase in NCI we observed with no alcohol consumption could not be explained by
abstinence related to prior hazardous consumption, as excluding the participants in this category
did not alter the U-shaped distribution. The neurocognitive profile of these participants at the
two-year NAMACO study follow-up is undergoing analysis to examine this association.
Adverse effects of HIV and alcoholism on specific neurocognitive domains have been
described. Fama and co-authors described two single-centre studies exploring the effect of
HIV, alcoholism and HIV plus alcoholism on neurocognitive function against neurocognitive
function among control participants with neither HIV nor alcoholism [27,28]. The number of
participants was smaller than in our study, with 36–42 participants per group, and the partici-
pants were younger, mean age 40–45 years old at baseline (compared to 54.5 years in our
study). This group observed that HIV and alcoholism were associated with decreased scores
on executive function and episodic memory compared to control participants. As well as
marked differences in sample size and participant age, the two studies reported by Fama and
co-authors differed from our study in several ways. First, this group defined alcoholism as
meeting DSM-IV criteria for alcohol dependence within three years prior to baseline study
entry rather than by using the AUDIT-C score. Second, they examined two neurocognitive
domains, first working and episodic memory [27] and then executive function and episodic
memory [28], rather than the range of neurocognitive domains we used. Third, they used a
computerised neuropsychological test battery, the MicroCog; our study used different neuro-
psychological tests and the assessment was performed by clinical neuropsychologists. The
association we observed in our study between alcohol consumption and impairment in motor
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skills and overall neurocognitive function may therefore be explained by both participant
demographic and methodological factors.
What our study adds to the effect of alcohol on NCI is the effect of binge drinking as
opposed to hazardous alcohol consumption per se. Binge drinking has been described in the
context of liver disease. In a population-based study of 6366 adults aged�30 years old (HIV
status not reported) set in Finland, weekly and monthly binge drinking was associated with an
increased risk for liver disease which was independent of average alcohol intake [29]. To our
knowledge, ours is the first study to report this association in the context of NCI.
Our study has limitations. All alcohol and drug use data were obtained at medical visits within
the SHCS and documented by the patients’ infectious diseases physicians rather than by anony-
mous questionnaire. As a result, the data may be subject to some recall and/or social desirability
bias. AUDIT-C scores were not supplemented with phosphatidylethanol measurements. We did
not apply formal diagnostic criteria for substance use but used data on substance type and fre-
quency of use. We did not adjust for smoking. However, smoking was not identified as a factor
associated with NCI in our NCI prevalence paper [18]. Another limitation is that the NAMACO
study did not include HIV-negative control participants. In this way, even though our study popu-
lation had excellent HIV control (96.2% with viral loads<50 copies/ml), the associations we pres-
ent between alcohol consumption and NCI should still be considered in the context of HIV
infection. Finally, women made up 20% of NAMACO study participants and fewer women than
men described hazardous drinking (29% versus 55%). Even though this left 57 female participants
with hazardous drinking, it is possible that we did not observe an effect of female sex on NCI due
to insufficient numbers. Against these limitations, we have compared the effect of alcohol con-
sumption in a well-characterised cohort with higher numbers of participants than described to
date [27,28]. Our study is novel in that, as well as applying Frascati criteria to examine overall
NCI, we examined the effect of alcohol consumption on specific neurocognitive domains, exam-
ining z-scores as well as the presence or absence of NCI. A strength of the NAMACO study is
that, as recent or previous hazardous drinking and abstention can influence NCI, and as the
course of NCI may change over time, our longitudinal analysis will add to the current cross-sec-
tional findings. Our study adds to the Veterans Aging Cohort Study by Williams et al., which
used the AUDIT-C score to examine the effect of alcohol consumption on HIV disease severity
over time [30]. This group examined several health parameters but not neurocognitive function.
Conclusions
This is the first large study conducted among aging PWH in the modern ART era to examine
the association between reported alcohol consumption and impairment in specific neurocogni-
tive domains. We observed that binge drinking, rather than alcohol consumption frequency or
quantity, was associated with NCI, both globally and in specific neurocognitive domains. Exam-
ining total AUDIT-C score, rather than the binge-drinking component, may therefore risk
missing patients at risk of NCI. Our findings could help to inform PWH of the potential hazard
of binge drinking in terms of later neurocognitive function. Our neurocognitive assessment at
two and four years from this baseline study will contribute to our understanding of the longitu-
dinal association between alcohol consumption and NCI among NAMACO study participants.
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